Ruxolitinib, a first-generation inhibitor of JAK1 and JAK2, was the first approved oral JAK inhibitor for the treatment of hematologic disorders, while it has also been investigated for the treatment of AD in the form of topical formulation. The gene discussed is JAK1; the disease is Alzheimer disease.